Company news

Vir Biotechnology, Inc. (NASDAQ:VIR) news

Every Vir Biotechnology, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Vir Biotechnology, Inc. stock analysis →

Press releases & updates

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026

Vireo Growth Receives Regulatory Approval and Completes Acquisition of PharmaCann Colorado Retail Assets

August 7, 2026

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 5, 2026

Vir Biotechnology Announces Chief Financial Officer Transition

July 24, 2026

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

July 22, 2026

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

June 10, 2026

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association fo...

May 18, 2026

Sotrovimab (Xevudy: Vir Biotechnology, GlaxoSmithKline) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecast...

May 11, 2026

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 6, 2026

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

May 5, 2026

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

April 23, 2026

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

April 16, 2026

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell ...

April 13, 2026

Vir Biotechnology to Participate in Upcoming Investor Conferences

February 26, 2026

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

February 25, 2026

Vir Biotechnology Announces Proposed Public Offering of Common Stock

February 24, 2026

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients ...

February 23, 2026

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR...

February 23, 2026

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 23, 2026

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

February 9, 2026

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

January 12, 2026

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

December 17, 2025

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Z...

December 16, 2025

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

November 19, 2025

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstra...

November 9, 2025

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

November 7, 2025

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 5, 2025

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

November 3, 2025

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

October 22, 2025

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-550...

October 9, 2025

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025

October 7, 2025

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 25, 2025

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6, 2025

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 6, 2025

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525...

July 24, 2025

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

July 22, 2025

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 14, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 20, 2025

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis...

May 9, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

April 30, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Live...

April 24, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

March 21, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

March 13, 2025

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

February 19, 2025

Older →